Imlifidase denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for imlifidase are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Imlifidase as Not FDA-Approved — and How to Appeal

Imlifidase (Idefirix) occupies an unusual regulatory position: it holds approval in the European Union but, as of this writing, does not hold standard FDA approval for use in the United States. Aetna's denial almost certainly rests on a coverage exclusion for drugs lacking FDA approval for the proposed indication. This is a defensible but not insurmountable denial, because federal law and Aetna's own exception pathways create several avenues for reconsideration.

## Why This Denial Is Appealable

Even when a drug lacks full FDA approval, coverage may still be required or granted under specific circumstances. First, verify whether the drug has received any FDA Breakthrough Therapy designation, Accelerated Approval, or is available under a clinical trial or expanded access (compassionate use) protocol — each of these carries distinct coverage implications under federal and state law. Second, for patients covered under ERISA-governed employer plans, the plan must provide a "full and fair review" of every denial under ERISA §503. Third, non-grandfathered plans subject to the ACA must allow an independent external review under ACA §2719, giving you access to a neutral third-party reviewer who is not employed by Aetna.

## Federal Appeal Framework

• Internal appeal deadline: Aetna's standard deadline is 180 days from the denial notice for non-urgent matters. Check your Explanation of Benefits (EOB) for the exact date.
• External review: After exhausting internal appeals (or if Aetna fails to decide in time), you may request independent external review. The external reviewer has up to 45 days to decide on standard reviews.
• Expedited review: If your condition is urgent or you are currently hospitalized, request expedited internal and external review simultaneously — decisions are typically required within 72 hours.
• State insurance department: File a parallel complaint with your state insurance commissioner at any stage.

## Documentation to Gather

• Diagnosis confirmation: Pathology reports, specialist notes, and imaging establishing the specific condition imlifidase is intended to treat.
• Prescriber letter of medical necessity: Your transplant or treating physician must explain why imlifidase is medically necessary, why no FDA-approved alternative achieves the same clinical objective, and cite relevant medical society guidance (e.g., applicable transplant society or nephrology guidelines) without quoting specific statistics.
• Regulatory and access pathway documentation: FDA expanded access (compassionate use) IND number if applicable; any FDA correspondence; EU approval documentation as supporting context.
• Prior treatment history: A dated list of all previously tried therapies with outcomes, demonstrating that standard alternatives were inadequate or contraindicated per the treating physician's clinical judgment.
• Medical literature: Peer-reviewed publications and any applicable society position statements supporting use in your specific indication — obtained from your physician.

## Criteria-Mapping Structure

Request a copy of Aetna's current clinical policy bulletin (CPB) for imlifidase or for "drugs without FDA approval." Then build a point-by-point response:

| Policy Requirement | Supporting Chart Evidence | |---|---| | Approved or recognized indication | Specialist note + diagnosis codes | | No adequate FDA-approved alternative | Prescriber letter addressing alternatives | | Consistent with accepted medical practice | Society guideline citation + literature | | Expanded access or protocol pathway | IND or protocol documentation |

A well-mapped appeal that directly rebuts each denial criterion substantially increases the likelihood of overturn at internal review or external review.